Study Details
Testing the Drug Iptacopan in People with Idiopathic Immune Complex Mediated Membraneoproliferative Glomerulonephritis
(IRB#: IRB_00175737)
Idiopathic immune complex mediated membraneoproliferative glomerulonephritis (IC-MPGN) is a rare, severe disorder of excessive activation of the alternative complement pathway (AP). AP is an important part of immune system in the body which provides protection against infections. However, an over-activated AP is believed to contribute to several kidney diseases, including IC-MPGN. This study will test a drug called Iptacopan to treat adults with this disorder. The study wants to see if the drug will help people and is safe. People in the study will be randomly chosen to be treated with Iptacopan or a placebo. The placebo looks like the drug but does not have the medication. Being in the study requires about 15 study visits at the study clinic over 21 months. Medical tests will be done during the study to track the health of participants.
- All genders
- Over 7 years old
- Healthy Volunteers
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Over 7 years old
Volunteers: Healthy Volunteers
Location: In Person
Inclusion Criteria
- Ages 12 years old to 59 years old
- Diagnosis of IC-MPGN as confirmed by kidney biopsy within 12 months prior to screening in adults and within 3 years of screening in adolescents
- Able to attend in person at the study clinic
Exclusion Criteria
- Participants who have received any cell or organ transplantation, including kidney transplantation
- History of drug or alcohol abuse within the 12 months prior to study treatment administration
- Already participating in another clinical study
- History of recurrent serious infections
Will I be paid for my time?
Yes
IRB#: IRB_00175737
PI: Raoul Nelson
Department: PEDIATRICS
Approval Date: 2025-04-16 06:00:00
Specialties: Pediatric Nephrology
I am Interested